Foresters Investment Management Company Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)

Foresters Investment Management Company Inc. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 448,554 shares of the company’s stock after selling 37,050 shares during the period. Johnson & Johnson accounts for about 1.1% of Foresters Investment Management Company Inc.’s investment portfolio, making the stock its 10th largest holding. Foresters Investment Management Company Inc.’s holdings in Johnson & Johnson were worth $57,886,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Evolution Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $40,000. Crewe Advisors LLC grew its stake in shares of Johnson & Johnson by 75.0% in the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after acquiring an additional 150 shares during the period. Horan Securities Inc. grew its stake in shares of Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after acquiring an additional 241 shares during the period. Stuart Chaussee & Associates Inc. grew its stake in shares of Johnson & Johnson by 20.7% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 80 shares during the period. Finally, Ruggie Capital Group grew its stake in shares of Johnson & Johnson by 342.5% in the fourth quarter. Ruggie Capital Group now owns 469 shares of the company’s stock worth $60,000 after acquiring an additional 363 shares during the period. 66.90% of the stock is owned by institutional investors.

Shares of NYSE JNJ opened at $141.68 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The company has a market cap of $367.86 billion, a P/E ratio of 17.32, a price-to-earnings-growth ratio of 2.39 and a beta of 0.70. Johnson & Johnson has a 12-month low of $120.11 and a 12-month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.06 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.68%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date of this dividend was Friday, May 24th. Johnson & Johnson’s payout ratio is 46.45%.

JNJ has been the subject of a number of research analyst reports. Citigroup lifted their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research note on Monday, February 25th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target for the company in a research note on Wednesday, March 27th. Raymond James lifted their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 17th. Finally, Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $147.30.

In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was bought at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2019/06/13/foresters-investment-management-company-inc-lowers-position-in-johnson-johnson-nysejnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply